Key result
Therapeutic strategies for canine congestive heart failure, including RAAS inhibitors, diuretics, and inodilators, are reviewed alongside novel therapeutic targets.
Why the study?
Congestive heart failure is a major cause of morbidity and mortality with increasing prevalence in dogs, driven in part by renin-angiotensin aldosterone system overactivation.
This review summarizes current and novel therapeutic targets, particularly RAAS modulation, for the management of congestive heart failure in dogs.
Review informs canine CHF management with RAAS and novel targets; leaves open prospective validation before adoption.
Congestive heart failure (CHF) is a major cause of morbidity and mortality with an increasing prevalence in human and canine populations. Similar to humans, overactivation of the renin-angiotensin aldosterone system is involved in the pathophysiology of CHF in dogs. Current therapeutic strategies for the management of canine CHF include the use of RAAS inhibitors, diuretics and inodilators. The present review summarizes data from our own research on the modulation of the renin-angiotensin cascade in dogs in dogs, together with new findings (including novel therapeutic targets) from the veterinary and the human literature.
No takes yet. Share an insight, caveat, or question.
Jonathan P. Mochel (2019) conducted a review in Congestive heart failure. Therapeutic targets for CHF was evaluated. Therapeutic strategies for canine congestive heart failure, including RAAS inhibitors, diuretics, and inodilators, are reviewed alongside novel therapeutic targets.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: